Cytokine therapy or structured treatment interruptions in HIV infection: which is best?
- 1 June 2002
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 3 (6) , 719-726
- https://doi.org/10.1517/14656566.3.6.719
Abstract
Continuous highly active antiretroviral therapy (HAART) is the treatment of choice for HIV patients in order to prevent opportunistic infection or AIDS-related morbidity and mortality. However, new HIV treatment strategies are needed to face the emerging problems related to long-term toxicities and failures of HAART. Moreover, total eradication and complete restoration of immune system function cannot be achieved by HAART alone. Therefore, in an attempt to increase the natural immunity of HIV-infected patients, immune-based therapies have been investigated. This review is intended to provide an update on the use of immune-based therapies, in particular structured treatment interruptions and cytokines, such as IL-2 and IFN-a, as potential stimulants of the immune system of patients with HIV-infections and to discuss risks and benefits of each alternative. Ongoing and future clinical trials will provide a rationale for their use in clinical practice and will determine how these strategies can be combined to...Keywords
This publication has 33 references indexed in Scilit:
- Control of HIV despite the Discontinuation of Antiretroviral TherapyNew England Journal of Medicine, 1999
- Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapyNature Medicine, 1999
- Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort studyThe Lancet, 1999
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1996
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation TimeScience, 1996
- Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection — A Preliminary StudyNew England Journal of Medicine, 1995
- Interleukin-2: Inception, Impact, and ImplicationsScience, 1988
- Activity of Interferons Alpha, Beta, and Gamma Against Human Immunodeficiency Virus Replication In VitroAIDS Research and Human Retroviruses, 1987
- Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.Journal of Clinical Investigation, 1983